Jeffrey V. Poulton serves as the Executive Vice President, Chief Financial Officer, and principal financial officer at Alnylam Pharmaceuticals Inc., a leading biopharmaceutical company focused on developing RNAi therapeutics. In his role, Poulton is responsible for overseeing the company's financial strategy, operations, and reporting, ensuring that Alnylam maintains a strong financial position as it advances its pipeline of innovative treatments for genetic diseases. Poulton brings extensive experience in the biotechnology and pharmaceutical industries to his position at Alnylam. Prior to joining the company in 2014, he held various senior financial roles at major organizations, including Vice President of Finance at Millennium Pharmaceuticals and Chief Financial Officer at Vertex Pharmaceuticals. Throughout his career, Poulton has demonstrated a keen ability to navigate complex financial landscapes, driving growth and value creation for the companies he has served. His strategic vision and leadership have been instrumental in guiding Alnylam's financial planning and resource allocation, supporting the company's mission to transform the lives of patients with serious diseases. Under Poulton's financial stewardship, Alnylam has achieved significant milestones, including the successful launch of multiple RNAi therapeutics and the establishment of a robust global commercial infrastructure. His contributions have been vital in securing the financial resources necessary to fund the company's research and development efforts, as well as its expansion into new markets. Poulton's dedication to Alnylam's success and his expertise in financial management continue to play a crucial role in the company's ongoing growth and its commitment to delivering groundbreaking treatments to patients worldwide.